Extended Data Fig. 10: Relationship between radiology and pathology and other clinical/biomarker correlates.
From: Association between pathologic response and survival after neoadjuvant therapy in lung cancer
a, Patients with LN involvement by imaging at baseline and by pathology at resection by treatment arm. b, Radiographic (BOR per RECIST1.1) and pathologic response (%RVT) in PT. c, Radiographic (BOR per RECIST1.1) and pathologic response (%RVT) in LN, across treatment arms. d, Radiographic (BOR per RECIST1.1) and pathologic response (%RVT) in LN by treatment arm. e, ctDNA clearance and pathologic response (%RVT) in PT. f, ctDNA clearance and pathologic response (%RVT) in LN, across treatment arms. g, ctDNA clearance and pathologic response (%RVT) in LN by treatment arm. BOR denotes best overall response; CR complete response; LN, lymph node; MPR, major pathologic response; NE, not evaluable; pCR, pathologic complete response; PD, progressive disease; PR, partial response; PT, primary tumor; RECIST1.1, Response Evaluation Criteria in Solid Tumors version 1.1; RVT, residual viable tumor; SD, stable disease. aData were not reported for 1 patient. bctDNA data were not available/not evaluable for 108 patients. cctDNA data were not available/not evaluable for 93 patients. dctDNA data were not available/not evaluable for 109 patients. ectDNA data were not available/not evaluable for 53 patients. fctDNA data were not available/not evaluable for 56 patients.
